AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36411426
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine (0.8 ml/kg)
Trial: 34786388
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg intravenous single dose one hour before TACE
Trial: 33098211
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg orally once daily for 3 months (n = 12)
Trial: 35240861
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment only (Control)
Trial: 32920808
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose edoxaban (HDER)
Trial: 32920808
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose edoxaban (LDER)
Trial: 35281950
Drug: PRP+VSD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP+VSD treatment (group D)
Trial: 32565319
Drug: External radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External radiation boost (5 × 3 Gy) followed by standard pelvic chemoradiation (25 × 2 Gy with concurrent capecitabine)
Trial: 32565319
Drug: Standard pelvic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pelvic chemoradiation (25 × 2 Gy with concurrent capecitabine) without boost
Trial: 34244284
Drug: Mechanical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical and oral antibiotic bowel preparation (MOABP) - 1g neomycin and 1g metronidazole two times on the day prior to surgery
Trial: 34244284
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (MBP) - identical placebo
Trial: 33159526
Drug: Ticagrelor (180-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) plus aspirin (300 to 325 mg on day 1 followed by 75 to 100 mg daily for days 2 to 30)
Trial: 33159526
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus aspirin (300 to 325 mg on day 1 followed by 75 to 100 mg daily for days 2 to 30)
Trial: 33159526
Drug: Ticagrelor (180-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) plus aspirin
Trial: 35510948
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (single 20 mg dose)
Trial: 34145906
Drug: Transitional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transitional care interventions (care continuity and coordination, medication management, symptom recognition, self-management)
Trial: 34529026
Drug: Weekly health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly health education via WeChat
Trial: 32919110
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 10 μg/day
Trial: 32919110
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 30 μg/day
Trial: 32057576
Drug: MVA‐BN‐RSV high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA‐BN‐RSV high dose (1 × 10^8 TCID50)
Trial: 32057576
Drug: MVA‐BN‐RSV low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA‐BN‐RSV low dose (1 × 10^7 TCID50)
Trial: 32057576
Drug: MVA‐BN‐RSV (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA‐BN‐RSV (both doses)
Trial: 32057576
Drug: MVA‐BN‐RSV combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA‐BN‐RSV combined high dose groups
Trial: 35668121
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution (reference food, GS)
Trial: 34620123
Drug: Oral carbohydrate-rich
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate-rich (Ch-R) supplement taken 2 hours before elective caesarean delivery
Trial: 34477469
Drug: Betaine (BET)
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine (BET) supplementation 2.4 g/day for 2 weeks
Trial: 34600848
Drug: Standard preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preoperative antibiotics
Trial: 34600848
Drug: Chlorhexidine skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine skin preparation and antibiotic pocket wash
Trial: 34236435
Drug: Zinc before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc before breakfast (ZBB) - 25 mg zinc as zinc gluconate taken in the fasted state 30 min before breakfast
Trial: 34236435
Drug: Zinc with
RxNorm normalized name: Zinc with Vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc with breakfast (ZWB) - 25 mg zinc as zinc gluconate taken with breakfast
Trial: 32758296
Drug: Bleaching treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching treatment with hydrogen peroxide 35% applied for 2 days (2×1 d)
Trial: 32758296
Drug: No bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bleaching treatment (control group)
Trial: 35899811
Drug: RTS,S/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 vaccine (three doses)
Trial: 35286196
Drug: RSV vaccine
RxNorm normalized name: RSV VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV vaccine administered to pregnant mothers
Trial: 36087116
Drug: Phytate group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytate group (380 mg capsule of calcium‐magnesium InsP6 every 24 h for 3 months)
Trial: 32302705
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) using methylene blue as a photosensitizer activated by red and infrared diode laser
Trial: 32302705
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) using red and infrared diode laser
Trial: 34254834
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with 25 mg vitamin B6 and 400 mg magnesium oxide (S)
Trial: 34254834
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low oxalate diet and B6/magnesium supplementation (DS)
Trial: 33323209
Drug: Hourly stand
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hourly stand prompt group
Trial: 33323209
Drug: 10,000 daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000 daily step prompt group
Trial: 34408569
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with house dust mite (HDM) for 24 months
Trial: 34408569
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment for 24 months
Trial: 34189249
Drug: 70 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg/day intepirdine
Trial: 34189249
Drug: 35 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg/day intepirdine
Trial: 33319444
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of controlled‐release morphine
Trial: 33149896
Drug: 3% NaOCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% NaOCl gel irrigating the canals without PUI
Trial: 33149896
Drug: 3% NaOCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% NaOCl gel with PUI
Trial: 35649241
Drug: 3.4 g
RxNorm normalized name: psyllium 3.4 g oral wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 g psyllium fiber supplementation twice a day for 1 week before surgery
Trial: 34514692
Drug: DAPA+SAXA+MET (10/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPA+SAXA+MET (10/5 mg)
Trial: 34514692
Drug: GLIM+MET (1-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLIM+MET (1-6 mg)
Trial: 33326891
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus antidepressant medications
Trial: 33900493
Drug: Caffeine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (100 mg three times daily)
Trial: 35476316
Drug: Fedratinib 400
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fedratinib 400 mg/day
Trial: 33401384
Drug: Brain Breaks®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain Breaks® video intervention for 3-5 min daily at low-to-moderate intensity for three months
Trial: 32968158
Drug: Thrice-weekly 3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly 3,000 IU cholecalciferol
Trial: 32968158
Drug: Once-monthly cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-monthly cholecalciferol (equivalent to 9,000 IU/week)
Trial: 32968158
Drug: Thrice-weekly placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly placebo
Trial: 32968158
Drug: Once-monthly placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-monthly placebo
Trial: 34103317
Drug: Cognitive‐behavioural therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioural therapy for insomnia (CBT‐I)
Trial: 32534584
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of methoxamine at 2 μg/kg/min
Trial: 32534584
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of normal saline (control)
Trial: 35257600
Drug: New antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antiretroviral drug as part of a combination antiretroviral treatment regimen
Trial: 38231017
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (HD-DXM)
Trial: 32371539
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for three cycles, followed by three adjuvant cycles, in combination with definitive radiotherapy.
Trial: 33219482
Drug: SAM vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAM vaginal gel (intravaginal daily dose for three 28-day periods)
Trial: 33219482
Drug: SAM vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAM vaginal gel
Trial: 35672894
Drug: Daily pulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pulmonary rehabilitation training including pursed-lip breathing (PLB) training, abdominal breathing training, skeletal muscle training, and coughing and expectoration training.
Trial: 35672894
Drug: Routine drug
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drug therapy, COPD knowledge education, and smoking cessation treatment (Control group).
Trial: 34574483
Drug: Hypoglycemia problem-solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia problem-solving program (HPSP), 8-week duration, 90 min weekly sessions
Trial: 32913632
Drug: Wet preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet preparation method
Trial: 34365570
Drug: Self-etching (SE)
RxNorm normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching (SE) agent 1 with PFS (SE1_PFS_Shofu)
Trial: 34365570
Drug: Self-etching (SE)
RxNorm normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching (SE) agent with PFS (SE_PFS_Kuraray)
Trial: 33197271
Drug: Dulaglutide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide (1.5 mg/weekly)
Trial: 36477889
Drug: 1.83 g
RxNorm normalized name: HOMOSALATE 3.61 g in 36 g / OCTOCRYLENE 0.98 g in 36 g / OCTISALATE 1.83 g in 36 g / AVOBENZONE 1.1 g in 36 g TOPICAL SPRAY [Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.83 g protein kg body mass−1 day−1 (HIGH)
Trial: 36477889
Drug: 1.20 g
RxNorm normalized name: OCTINOXATE 1.5 g in 30 g / TITANIUM DIOXIDE 1.20 g in 30 g TOPICAL LOTION [Sun Essential]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.20 g protein kg body mass−1 day−1 (MOD)
Trial: 36477889
Drug: 0.94 g
RxNorm normalized name: BUPHENYL 0.94 GM/GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.94 g protein kg body mass−1 day−1 (LOW)
Trial: 32075475
Drug: ASP1707 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP1707 30 mg twice daily
Trial: 34579560
Drug: Topiramate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (100 mg/day)
Trial: 34115064
Drug: Different masses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different masses of bone substitute (12.5 mg and 25 mg)
Trial: 34607285
Drug: Nivolumab 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy
Trial: 34607285
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (four cycles)
Trial: 34607285
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs
Trial: 32171815
Drug: Educational video
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational video and patient information leaflet targeting misconceptions of topical corticosteroids
Trial: 32185840
Drug: ART with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART with protease inhibitors (PI)
Trial: 32185840
Drug: ART without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART without protease inhibitors (PI)
Trial: 32185840
Drug: ART with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART with protease inhibitors (PI) after excluding women with detectable viral load and CD4+ T-cell count <200
Trial: 32185840
Drug: ART without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART without protease inhibitors (PI) after excluding women with detectable viral load and CD4+ T-cell count <200
Trial: 33773357
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for 24 weeks
Trial: 33773357
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy or supportive psychotherapy
Trial: 35816306
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection and exercise therapy
Trial: 35816306
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection and exercise therapy
Trial: 34086195
Drug: Provision of
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provision of operative treatment post-DGA
Trial: 36304817
Drug: FF-20 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF-20 (1000 mg, delivering 192 mg fisetin)
Trial: 36304817
Drug: UF (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UF (1000 mg)
Trial: 33025926
Drug: Insulin Syringe
RxNorm normalized name: Insulin Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Syringe (IS)
Trial: 33306564
Drug: Smart-pill bottle
RxNorm normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smart-pill bottle service
Trial: 33306564
Drug: Smart-pill bottle
RxNorm normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smart-pill bottle service (after excluding 3 participants with drug-drug interactions)
Trial: 33306564
Drug: Control arms
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arms (after excluding 3 participants with drug-drug interactions)
Trial: 36041732
Drug: Fructose and
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose and rice (2 g/kg of CHOs in a CHO ratio of 1:2)
Trial: 36041732
Drug: Glucose and
RxNorm normalized name: Glucose and treacle only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose and rice (2 g/kg of CHOs in a CHO ratio of 1:2)
Trial: 33772433
Drug: Nebulized magnesium
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized magnesium sulphate (3 mL of 3.2% MgSO4 every 4 hours for 24 hours)
Trial: 32253548
Drug: Multiple-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose intravenous tranexamic acid (TXA) administered before incision, 3, 6, 12, 18, and 24 hours later (Group D)
Trial: 32253548
Drug: Multiple-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose intravenous tranexamic acid (TXA) (Group D)
Trial: 32498372
Drug: Probiotic Lactobacillus
RxNorm normalized name: Probiotic Lactobacillus Acidophilus Caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Lactobacillus casei Shirota (LcS), three times daily for six months
Trial: 33451648
Drug: High-density peptide
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-density peptide arrays screening of twelve leading vaccine candidates as overlapping 15-mer peptides.
Trial: 34928484
Drug: Ramucirumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (10 mg/kg intravenously every 2 weeks) plus Erlotinib (150 mg/day orally)
Trial: 34928484
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Erlotinib (150 mg/day orally)
Trial: 36881395
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapies (GDMT)
Trial: 34189606
Drug: Oral Health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Health Education and Prevention Program (OHEPP)
Trial: 32711612
Drug: NAB PC
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NAB PC (albumin‐binding paclitaxel 130 mg/mL, D1, D; carboplatin AUC = 6, D1)
Trial: 32711612
Drug: PC (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC (paclitaxel 175 mg/mL, D1; carboplatin AUC = 6, D1)
Trial: 32950674
Drug: Corticosteroid Injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid Injection (CS)
Trial: 36053506
Drug: Bedaquiline-Pretomanid-Linezolid with
RxNorm normalized name: pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 1200 mg for 26 weeks
Trial: 36053506
Drug: Bedaquiline-Pretomanid-Linezolid with
RxNorm normalized name: pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 1200 mg for 9 weeks
Trial: 36053506
Drug: Bedaquiline-Pretomanid-Linezolid with
RxNorm normalized name: pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 600 mg for 26 weeks
Trial: 36053506
Drug: Bedaquiline-Pretomanid-Linezolid with
RxNorm normalized name: pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bedaquiline-Pretomanid-Linezolid with linezolid at a dose of 600 mg for 9 weeks
Trial: 34023009
Drug: Upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 15 mg plus topical corticosteroids
Trial: 34023009
Drug: Upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 30 mg plus topical corticosteroids
Trial: 35665810
Drug: GAD-alum (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-alum (4 μg) with oral vitamin D